Arrowhead Research Stock Earnings Reports

Arrowhead reported a productive quarter highlighted by its first regulatory approval and commercial launch. The FDA approved REDEMPLO (plozasiran) for adults with familial chylomicronemia syndrome (FCS); Arrowhead launched the drug in the U.S. with a One-REDEMPLO pricing model and has received early encouraging uptake (over 100 prescriptions within ~10 weeks) and positive payer feedback. REDEMPLO also received approvals in Canada and China; launches in Canada (Arrowhead) and Greater China (Sanofi) are planned. The cardiometabolic pipeline remains active: Phase III registrational studies for plozasiran in severe hypertriglyceridemia (SHASTA-3/4 and MUIR-3) are on track to complete their blinded portions mid-2026 with topline data expected in Q3 2026 and a planned sNDA by year-end. Early obesity programs (ARO-INHBE and ARO-ALK7) showed promising interim signals—enhanced weight and fat loss versus tirzepatide alone—prompting cohort expansions and further data later in 2026. Arrowhead also dosed the first patients in ARO-DIMER-PA (dual PCSK9/APOC3) with interim data expected H2 2026. In CNS, the novel subcutaneous blood–brain-barrier delivery platform advanced: ARO-MAPT (tau) is in Phase I/II with healthy-volunteer data expected in 2026 and patient data in 2027; SRP-1005 (Huntington’s) is partnered with Sarepta and progressing. Strategic deals materially bolstered finances: a collaboration with Novartis for ARO-SNCA ($200M upfront; up to $2B milestones + royalties), a $200M Sarepta milestone, and concurrent financings ($700M convertible notes and $230M equity). Reported cash & investments were ~$917M (not including subsequent milestone/payments and recent financings), and the company reported net income of $30.8M for the quarter driven largely by collaboration/license revenue. Operating expenses rose year-over-year as R&D (notably the SHASTA programs) and SG&A (commercial build for REDEMPLO) increased. Key 2026 catalysts: continued REDEMPLO commercial ramp, Q3 SHASTA-3/4 topline for SHTG, H2 ARO-DIMER-PA interim data, more obesity and ARO-MAPT data, and potential additional platform/partnership announcements. Risks include early-stage commercial ramp uncertainty, payer coverage negotiations, ongoing trial readouts, and the usual development/regulatory risks noted in SEC filings.